Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-10-06
1998-06-16
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 18, 514851, 530300, 530329, 530330, A61K 3807, A61K 3808, C07K 5103, C07K 706
Patent
active
057670846
ABSTRACT:
Peptides derived from mutant CFTR protein which inhibit intracellular degradation and/or retention of mutant CFTR proteins are disclosed. A method of inhibiting intracellular degradation and/or retention of mutant CFTR protein by administering peptides having an amino acid sequence corresponding to mutant CFTR amino acid sequences is also disclosed. Further, a method of preventing cellular retention and degradation of an otherwise membrane bound protein by competitively inhibiting intracellular degradation (proteolysis) and retention which would otherwise retain or degrade synthesized mutant proteins prior to arrival of the protein at the cell surface is disclosed.
REFERENCES:
patent: 4439196 (1984-03-01), Higuchi
patent: 4447224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4475196 (1984-10-01), La Zor
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5077276 (1991-12-01), Ballard et al.
patent: 5167616 (1992-12-01), Haak et al.
patent: 5169383 (1992-12-01), Gyory et al.
patent: 5225182 (1993-07-01), Sharma
patent: 5358934 (1994-10-01), Borovsky et al.
Sato et al. Glycerol Reverses the Misfolding Phenotype. J. of Biol. Chem. 12 Jan. 1996, vol. 271, No. 2, pp. 635-638.
Jones et al. Molecular Cloning and Transcript Mapping. Mol. Gen. Genet. 1989. vol. 219, pp. 397-403.
Boat et al., "Cystic Fibrosis" In C.R. Schriver, A.L. Beudet, W S Sly, and D. Valle. Editors. The Metabolic Basis of Inherited Disease, 6th ed. McGraw-Hill, New York 2649-2680 (1989).
Boucher et al., "Na.sup.+ Transport in Cystic Fibrosis Respiratory Epithelial: Abnormal Basal Rate and Response to Adenylate Cyclase Activation". J. Clin. Invest., 78:1245-1252 (1986).
Cheng et al., "Defective Intracellular Transport and Processing of CFTR Is The Molecular Basis of Most Cystic Fibrosis" Cell, 63, 827-834 (1990).
Ciaccia and Price, Immumohistochemistry of Recombinant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Expressed in Insect Cells: IBI FLAG Epitope, 1, 4-5 (1992).
Denning et al., "Processing of Mutant Cystic Fibrosis Transmembrane Conductance Regulator is Temperature-Sensitive" Nature, 358, 761-764 (1992).
Frizzell et al., "Altered Regulation of Airway Epithelial Cell Chloride Channels in Cystic Fibrosis" Science, 233:558-560 (1986).
Knowles et al., "Abnormal Ion Permeation Through Cystic Fibrosis Respiratory Epithelium" Science, 221:1067-1070 (1983).
Li et al., "The Cystic Fibrosis Mutation (.increment.F508) Does Not Influence The Chloride Channel Activity of CFTR" Nature Genetics, 3, 311-316 (1993).
Lukacs et al., "The .increment.F508 Mutation Decreases The Stability of Cystic Fibrosis Transmembrane Conductance Regulator In The Plasma Membrane" J. Biol. Chem., 268, 21592-21598 (1993).
Pind et al., Participation of the Endoplasmic Reticulum Chaperone Calnexin (p88, IP90) in the Biogenesis of the Cystic Fibrosis Transmembrane . . . J. Biol. Chem., 269, 12784-12788 (1994).
Quinton, "Chloride Impermeability In Cystic Fibrosis" Nature, 301:421-422 (1983).
Quinton, "Cystic Fibrosis: A Disease in Electrolyte Transport" FASEB J., 4:2709-2717 (1990).
Riordan et al., "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA" Science, 245:1066-1073 (1989).
Sarkadi et al., "Biochemical Characterization of the Cystic Fibrosis Transmembrane Conductance Regulator in Normal and Cystic Fibrosis Epithelial Cells" J. Biol. Chem., 267, 2087-2095 (1992).
Welsh and Smith, "Molecular Mechanism of CFTR Chloride Channel Dysfunction in Cystic Fibrosis" Cell, vol. 73, 1251-1254 (1993).
Yang et al., The Common Variant of Cystic Fibrosis Transmembrane Conductance Regulator is Recognized by hsp70 and degraded in a Pre-Golgi . . . : Proc. Natl. Acad. Sci. USA, 90, 9480-9484 (1993).
Clarke Lane L.
Price Elmer M.
Russel Jeffrey E.
The Curators of the University of Missouri
LandOfFree
Method of treatment for cystic fibrosis and peptides for same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment for cystic fibrosis and peptides for same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment for cystic fibrosis and peptides for same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1726112